TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 18, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2025

Conditions
Glioblastoma
Interventions
DRUG

TN-TC11G

"TN-TC11G dose will be gradually increased as follows:~Week 1: TN-TC11G: 0-0-5 mg (THC 5 mg + CBD 5 mg; in the mornings, 90 minutes after breakfast; in the afternoons, 90 minutes after lunch; in the evenings, 90 minutes after dinner).~Week 2: TN-TC11G: 5-0-5 mg Week 3: TN-TC11G: 5-5-5 mg Week 4: TN-TC11G: 5-5-10 mg Week 5: TN-TC11G: 5-5-15 mg Week 6: TN-TC11G: 10-10-15 mg Week 7: TN-TC11G: 10-10-20 mg. Week 8: TN-TC11G: 15-15-30 mg Week 9: TN-TC11G: 20-20-40 mg TN-TC11G will be administered daily at the relevant dose level according to the individual titration performed in the first 9 weeks of treatment. If there is any dose reduction, the reduced dose must be administered."

DRUG

Temozolomide Oral Product

"During RT, patients will receive Temozolomide (TMZ). All patients will be given TMZ at 75 mg/m2/d concurrently with RT for a maximum of 42 days.~At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles."

RADIATION

Radiotherapy

All the patients will receive the Stupp regimen. The radiotherapy (RT) treatment will be administered in fractions of 1.8-2.0 Gy/day delivered 5 days/week to a total dose of 58-60 Gy. Radiotherapy will be delivered to the gross tumor volume with a 2-3 cm margin for the clinical target volume.

Trial Locations (8)

18004

Complejo Hospitalario Regional Virgen de las Nieves, Granada

28041

Hospital Universitario 12 de Octubre, Madrid

37007

Hospital Clínico Universitario de Salamanca, Salamanca

41013

Hospital Universitario Virgen del Rocío, Seville

08908

Institut Català d'Oncología L'Hospitalet, L'Hospitalet de Llobregat

Unknown

Hospital Universitario Son Espases, Palma de Mallorca

Hospital Regional Universitario de Malaga, Málaga

08003

Hospital del Mar, Barcelona

All Listed Sponsors
collaborator

Medical Cannabis Bike Tour

UNKNOWN

collaborator

Voices Against Brain Cancer

UNKNOWN

collaborator

Tilray

INDUSTRY

lead

Grupo Español de Investigación en Neurooncología

OTHER

NCT03529448 - TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma | Biotech Hunter | Biotech Hunter